Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the EU / 2025-525122-35-00
Authorised, not yet recruiting Phase IV

Attachment Development and Learning in ADHD: The Role of Dopamine.

2025-525122-35-00 · tracked via the Priya Life Science EU tracker
Sponsor
UZ Leuven
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Mental Disorders
Decision date
15/09/2026
Enrollment target
64
Sites
Belgium

Condition studied

Attention-Deficit/Hyperactivity Disorder (ADHD)

Investigational medicinal product(s)

Rilatine 10 mg TablettenDescription: Whiteroundflatwith beveled edges. One side bears the imprint "CG"the other “A/B" and score. May contain dark specks. Diameter: about 7.0 mm.Thickness: about 2.6 mm. Composition: Ingredient Amount per tablet [mg] Function Reference Wheat starch 51,69 DiluentBinderDisintegrant Ph. Eur. Lactosemonohydrate 43,08 Diluent Ph. Eur. Calcium phosphatetribasic 37,69 Diluent Ph. Eur. Waterpurified1 - - Ph. Eur. Talc 6,03 Glidant Ph. Eur. Gelatin 1,08 Binder Ph. Eur. Magnesium stearate 0,43 Lubricant Ph. Eur. Total weight 140,0 Packaging: PA/AL/PVC blister pack backed with a heat-sealable lacquered aluminum foil. The manufacturing process of the tablets consists of a traditional wet granulation process which is carried out according to standard pharmaceutical procedures of wettingmassing/kneadingdryingsievingmixing and tableting.

Eligibility

Age group
0-17 years
Sex
Female, Male

Primary endpoint

Children’s instrumental responding to caregiver-related cues compared to neutral cues; children’s trust learning and support-seeking behavior; behavioral-based rating of children’s attachment representations and parental sensitivity; immediate affective relationship dynamics.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-525122-35-00 on CTIS ↗ ← All trials in the EU